Navigation Links
Phase 2b Study of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Shows Undetectable Virus in HCV Genotype-1 Patients 12 Weeks After Treatment Ended (SVR12)
Date:4/19/2012

ot available due to treatment duration  

Investigators reported breakthrough broken out by genotype and IL-28B status. In GT1b and GT1a-CC patients, breakthrough occurred in 7 percent of patients in Arm A, 11 percent of patients in Arm B, 19 percent of patients in Arm C, 9 percent of patients in Arm D, and 29 percent of patients in Arm E (no RBV arm). In GT1a non-CC patients, breakthrough occurred in 40 percent of patients in Arm A, 50 percent of patients in Arm B, 25 percent of patients in Arm C, 64 percent of patients in Arm D, and 91 percent of patients in Arm E (no RBV arm).

In this study, the most common adverse events (AEs) were skin (photosensitivity, rash), gastrointestinal (GI) disorders (vomiting, diarrhea), and jaundice due to unconjugated hyperbilirubinemia. Treatment discontinuations due to AEs correlated with increased dosing frequency and treatment duration, with discontinuations ranging from 4.9 percent in Arm A (16 weeks) to 24.7 percent in Arm C (40 weeks). In the arm with BID dosing of BI 207127 (Arm D), discontinuations were 7.7 percent. BID dosing of BI 207127 is planned for Phase 3 investigation.

Other BI data being presented at the EASL Annual Meeting include: Poster PresentationsTitleLead Author Presentation Details SOUND-C2 interim analysis:
The efficacy and safety of the
interferon-free combination of
BI 201335 and BI 207127 in
genotype-1 HCV patients with
cirrhosis

V. Soriano

Late Breaker Poster# 1420

 

Date: Thur, April 19

Time: 12:00 - 1:30 p.m.
CEST/ 6:00 - 7:30 a.m. EDT

 Characterization of HCV NS3
variants that emerged during
virologic breakthrough and
relapse from BI 201335 Phase
2 SILEN-C2 study in
pegylated-interferon plus
ribavirin treatment-
experienced patients

G. Kukolj

Poster# 1185

 

Date: Sat, April 21

Time: 12:30 – 1:30 p.m.
CEST/ 6:30 &
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CrystalGenomics Announces Positive Results from Phase 2b Osteoarthritis Study of CG100649
2. Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer
3. Encouraging Phase III Study Results Show PET Imaging with Florbetaben Reliably Detects Beta-Amyloid in the Brain
4. QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR
5. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
6. UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
7. Bionovos Independent Data Safety Monitoring Board Recommends Continuation of Phase 3 Study for Menerba™
8. Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia
9. iBio Announces Successful Completion of H1N1 Influenza Vaccine Phase 1 Clinical Trial
10. Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease
11. Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiologys Annual Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Cepheid (Nasdaq: ... group purchasing contract with Premier will end on ... Premier GPO will be able to continue their ... Baycare, HPA, MedAssets, Novation, and ROi, in addition ... directly with Cepheid. "Cepheid has always ...
(Date:7/30/2014)... , July 30, 2014  Unilife Corporation ("Unilife" ... a developer and supplier of injectable drug delivery ... manufacturing capacity, R&D, and facilities in response to ... its products and services. During the fourth quarter ... $16 million in capital expenditures and R&D above ...
(Date:7/30/2014)... Research and Markets has announced the addition of the ... report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... lower CAGR in developed countries; however, it is expected to witness ... , India , and Brazil ... the hematology analyzers and reagents market is driven by factors such ...
Breaking Medicine Technology:Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Hematology Analyzers & Reagents Market - Forecasts to 2019 2
(Date:7/30/2014)... Andover, NJ (PRWEB) July 30, 2014 Within weeks ... with excitement and promise. Each hopes this will be a time ... is reason for each to pause; it may not be as ... as 80% of students will switch their major at least once ... cost time and energy and the costs are exacerbated when switching ...
(Date:7/30/2014)... 30, 2014 Conducting Advanced Root ... Thinking Skills and Innovative Techniques to Improve the ... and FDAnews**, Sept. 17-18, 2014 – Raleigh, NC, ... #1 reason for 483 observations since 1997. , ... a successful CAPA program has never been more ...
(Date:7/30/2014)... Good Neighbor Community Services announced ... episode of Innovations with Ed Begley Jr, airing ... show times TBA. , In this segment, viewers ... vision to redefine the traditional approach to serving ... Through passion, innovation, determination, excellence, and collaboration, Good ...
(Date:7/30/2014)... 30, 2014 SF Cable, distributor of ... lowest prices on the internet with guaranteed customer satisfaction ... lengths and two colors. These lightning cords are MFI ... The high quality SF Cable Lightning to USB ... signal delivering faster charging and syncing. Compatible with the ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery is ... office on July 30th. After months of planning, Dr. ... the state-of-the-art suite, located only steps away from the ... for one-on-one patient comfort, shorter wait times, and generally ... Hamilton’s new office-suite will continue to provide the same ...
Breaking Medicine News(10 mins):Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2
... As injectable fillers,become mainstream it is no surprise ... alternatives to prevent facial wrinkles. Dr. Arnold,Klein, world-renowned ... says, "Fillers such as Artefill, Radiesse and Sculptra,contain ... into,human tissue, all of these products can cause ...
... ARLINGTON, Va., May 8 Who says the best,times ... The HealthCentral Network, Inc. (http://www.HealthCentral.com ) has recently,brought ... prove that along,with wrinkles and the responsibility of caring ... bring a smile to the face of others., ...
... An international,organization dedicated to furthering the advancement ... (GSK) Consumer Healthcare executive today,during an awards ... Ernestine Harris,GSK Consumer Healthcare,s U.S. director of ... Star" by the Healthcare Businesswomen,s Association,(HBA). The ...
... with human immunodeficiency virus (HIV), which leads to acquired ... According to the most recent estimates, released in ... HIV/AIDS (UNAIDS) and the World Health Organization (WHO), an ... currently. Although the rates of infection appear to ...
... Hill-Rom Holdings,Inc., (NYSE: HRC ) invites ... H.,Soderberg, president and chief executive officer, Hill-Rom. He ... New York on Wednesday, May 21,at 8:30 a.m. ... the live presentation via the internet,link at ...
... ("MDAC") is proud to announce that it has retained ... build a significant enterprise in one or,more select medical ... MDAC team combines a strong set of capabilities and ... excited to be working,with them in identifying and executing ...
Cached Medicine News:Health News:Dr. Arnold Klein Warns of Dangers With Permanent and Longer Lasting Injectable Fillers 2Health News:The HealthCentral Network Signs Spunky 'Midlife Gals' for Comedic Relief on Alzheimer's, Skin Care Sites 2Health News:GSK's Ernestine Harris Honored as Industry 'Rising Star' by Healthcare Businesswomen's Association 2Health News:GSK's Ernestine Harris Honored as Industry 'Rising Star' by Healthcare Businesswomen's Association 3Health News:Do antidepressants enhance immune function? 2
... flow while minimizing the pain ... the safety-engineered BD Microtainer Genie ... Lancet offers a full range ... capillary blood collection and protects ...
... Maximize blood flow and minimize pain ... the safety-engineered BD Microtainer Quikheel Lancet. ... surgical blade providing a precise and ... retracts into its casing, helping to ...
DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading....
The Minilyser offers a combination of three well proven instruments for fully automated processing of microplates. The Minilyser is the optimal fully automated ELISA and EIA equipment for laboratorie...
Medicine Products: